The Overview
Novartis announced it will present 46 abstracts from its multiple sclerosis (MS) portfolio at MSToronto2026, the 10th Joint ACTRIMS-ECTRIMS Meeting, on October 07, 2026. The presentation will include late-breaking Phase III REMODEL-1/-2 trial results for remibrutinib, an oral BTK inhibitor, showcasing its efficacy and safety in relapsing multiple sclerosis (RMS). Additionally, new Kesimpta (ofatumumab) data will be featured, specifically from the Phase III NEOS study in pediatric MS, and expanded evidence from the STHENOS and KATHAROS studies, aiming to address significant unmet needs across various patient populations and disease stages.
Knolens Analysis
At a Glance
| Indication | Multiple sclerosis |
| Drug | Remibrutinib |
| Mechanism of Action | BTK inhibitor |
| Company | Novartis |
| Trial Phase | Phase III |
| Trial Acronym | REMODEL-1/-2 |
| Category | Clinical Trial Event |
| Sub Category | Topline Results Positive |
| Therapeutic Area | Neuroscience |
| Conference Name | MSToronto2026, 10th Joint ACTRIMS-ECTRIMS Meeting |
| Number of Abstracts | 46 |
| Comparator Drug (REMODEL) | Teriflunomide |
| Additional Drug Highlighted | Kesimpta (ofatumumab) |
| Patient Population (NEOS Study) | Pediatric Multiple Sclerosis |
| Study Focus (KATHAROS) | Breastfeeding outcomes |
| Study Focus (PRIM) | Pregnancy and infant outcomes |
| Remibrutinib Presentation Time | October 23, 11:25 – 11:35 a.m. ET |
| Kesimpta NEOS Presentation Time | October 23, 11:15 – 11:25 a.m. ET |
| Press Release Date | October 07, 2026 |
Novartis Unveils Late-Breaking MS Data at MSToronto2026
Novartis announced it will present 46 abstracts from its multiple sclerosis (MS) portfolio at MSToronto2026, the 10th Joint ACTRIMS-ECTRIMS Meeting, on October 07, 2026. The presentation will include late-breaking Phase III REMODEL-1/-2 trial results for remibrutinib, an oral BTK inhibitor, showcasing its efficacy and safety in relapsing multiple sclerosis (RMS). Additionally, new Kesimpta (ofatumumab) data will be featured, specifically from the Phase III NEOS study in pediatric MS, and expanded evidence from the STHENOS and KATHAROS studies, aiming to address significant unmet needs across various patient populations and disease stages.
- Novartis will present late-breaking Phase III REMODEL-1 and REMODEL-2 trial results for remibrutinib, an oral BTK inhibitor, at MSToronto2026. These studies evaluate the efficacy and safety profile of remibrutinib compared to teriflunomide in relapsing multiple sclerosis, underscoring its potential to advance care for people living with MS.
- New late-breaking data for Kesimpta (ofatumumab) from the Phase III NEOS study will be highlighted, focusing on its efficacy and safety in pediatric multiple sclerosis, an area with limited approved treatment options. Further presentations will expand the Kesimpta evidence base, including research from the STHENOS study in treatment-naive relapsing MS and the KATHAROS breastfeeding study, to inform family planning decisions.
- The comprehensive presentation of 46 abstracts from Novartis's MS portfolio at the 10th Joint ACTRIMS-ECTRIMS Meeting demonstrates the company's sustained commitment to scientific innovation in multiple sclerosis. These data, encompassing both remibrutinib and Kesimpta, reflect Novartis's strategy to address diverse unmet needs across different stages of life and disease, reinforcing its leadership in the MS treatment landscape.
Frequently Asked Questions
What is the latest news on multiple sclerosis?
Recent developments in multiple sclerosis include the December 2022 FDA approval of ublituximab (Briumvi) for relapsing forms of MS, providing another anti-CD20 monoclonal antibody. Furthermore, Bruton's tyrosine kinase (BTK) inhibitors remain a significant focus in late-stage clinical development, with ongoing Phase 3 trials for several agents like tolebrutinib, evobrutinib, and fenebrutinib, despite some recent trial modifications related to safety signals.
How hard is it to live with MS?
Living with Multiple Sclerosis presents significant challenges due to its unpredictable and highly variable nature, ranging from mild symptoms to severe disability. Patients often experience chronic fatigue, motor and sensory deficits, cognitive impairment, and pain, which profoundly impact daily activities, employment, and quality of life. The progressive nature of the disease for many, coupled with the need for continuous management and potential for relapses, necessitates substantial adaptation and resilience.
Is autophagy beneficial for multiple sclerosis?
Autophagy's role in multiple sclerosis (MS) is complex, but emerging evidence suggests it can be beneficial by promoting cellular clearance, modulating immune responses, and supporting neuroprotection and remyelination. Dysregulation of autophagy is implicated in MS pathogenesis, and therapeutic strategies aimed at restoring or enhancing specific autophagic pathways are under investigation. Controlled modulation of autophagy holds promise as a therapeutic target to mitigate neuroinflammation and neurodegeneration in MS.
What are the treatment options for multiple sclerosis (MS)?
Treatment for multiple sclerosis primarily involves disease-modifying therapies (DMTs) to reduce relapse frequency, severity, and slow disability progression. These include a range of injectable, oral, and infused agents targeting various immunological pathways. Acute relapses are typically managed with high-dose corticosteroids, while a variety of medications and non-pharmacological interventions address specific MS symptoms like fatigue, spasticity, and pain.
What is the best treatment for multiple sclerosis?
There is no single "best" treatment for multiple sclerosis, as optimal therapy is highly individualized based on disease subtype, activity, progression, patient comorbidities, and risk tolerance. Disease-modifying therapies (DMTs) are the cornerstone of treatment, aiming to reduce relapse rates, slow disability progression, and minimize new lesion formation. These range from platform injectables to high-efficacy oral and infused agents, with treatment selection guided by a shared decision-making process considering efficacy, safety profiles, and patient-specific factors. Symptomatic treatments are also crucial for managing the diverse manifestations of MS.
How do you accept you have MS?
Accepting an MS diagnosis is a complex, ongoing psychological process, not a singular event. It involves grieving the loss of previous health, adjusting to new physical limitations, and integrating the disease into one's identity. This journey often requires developing new coping strategies, seeking emotional support from healthcare professionals or peer groups, and adapting daily life to manage symptoms and disease progression. Ultimately, acceptance means acknowledging the reality of MS while focusing on proactive management and maintaining quality of life.
Do people with MS still work?
Many individuals with multiple sclerosis (MS) continue to work, though employment rates are significantly lower compared to the general population. Disease progression, symptom burden (e.g., fatigue, cognitive impairment), and disability accumulation often lead to reduced work hours or early retirement. However, advancements in disease-modifying therapies and improved symptom management strategies, alongside workplace accommodations, enable many to maintain employment for extended periods. The ability to work varies widely depending on disease subtype, individual circumstances, and access to supportive resources.
Contact Us
📍
Address
350 Springfield Avenue,
Suite #200 Summit, NJ 07901
✉️
For General Inquiry
info@pienomial.com
